patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_599253 | REC_0012901 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 29 | 3.2 | 86 | female | 1 | 15 | 3.4 | 1 | pembrolizumab 200 mg q3w | 15.4 | false | MSS | 2026-03-15T05:36:00.151821+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_806640 | REC_0012902 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 10.4 | 70 | female | 2 | 9 | 4.3 | 1 | sotorasib 960 mg daily | 24.9 | false | MSS | 2026-03-15T05:36:00.152305+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_412958 | REC_0012903 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 4.3 | 60 | male | 0 | 49 | 5.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 31.5 | true | MSS | 2026-03-15T05:36:00.152686+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_148026 | REC_0012904 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 11.4 | 62 | male | 1 | 7 | 4.8 | 6 | alectinib 600 mg BID | 9.2 | false | MSI-H | 2026-03-15T05:36:00.153010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_513054 | REC_0012905 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 7.2 | 61 | female | 1 | 20 | 6.2 | 2 | osimertinib 80 mg daily | 16.3 | false | MSS | 2026-03-15T05:36:00.153307+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_487658 | REC_0012906 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 5.4 | 69 | female | 0 | 43 | 5.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 10.3 | true | MSS | 2026-03-15T05:36:00.153587+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_953995 | REC_0012907 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 13 | 18.3 | 46 | female | 0 | 7 | 6.6 | 5 | osimertinib 80 mg daily | 10.8 | false | MSS | 2026-03-15T05:36:00.153864+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_638734 | REC_0012908 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 15.3 | 67 | female | 0 | 12 | 4.7 | 2 | entrectinib 600 mg daily | 10.4 | false | MSI-H | 2026-03-15T05:36:00.154222+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_454913 | REC_0012909 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 22 | 13 | 68 | female | 1 | 16 | 4.1 | 2 | pembrolizumab 200 mg q3w | 19.3 | true | MSS | 2026-03-15T05:36:00.154535+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_555652 | REC_0012910 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 7.2 | 54 | male | 0 | 15 | 5.8 | 5 | osimertinib 80 mg daily | 7.6 | false | MSS | 2026-03-15T05:36:00.155006+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_786545 | REC_0012911 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 17 | 64 | female | 0 | 25 | 4.1 | 5 | osimertinib 80 mg daily | 16.1 | false | MSI-H | 2026-03-15T05:36:00.155342+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_346808 | REC_0012912 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 9.6 | 63 | female | 1 | 11 | 4.5 | 6 | osimertinib 80 mg daily | 4.2 | true | MSS | 2026-03-15T05:36:00.155634+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_378984 | REC_0012913 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 33 | 16.4 | 68 | male | 1 | 3 | 4.2 | 6 | osimertinib 80 mg daily | 9.6 | true | MSI-H | 2026-03-15T05:36:00.155911+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931148 | REC_0012914 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 12.3 | 70 | female | 0 | 10 | 5.4 | 5 | alectinib 600 mg BID | 14.8 | false | MSS | 2026-03-15T05:36:00.156248+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_513725 | REC_0012915 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 21.4 | 70 | female | 2 | 22 | 6.6 | 3 | sotorasib 960 mg daily | 11 | false | MSI-H | 2026-03-15T05:36:00.156584+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_213400 | REC_0012916 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 9.4 | 76 | female | 2 | 13 | 6.9 | 7 | osimertinib 80 mg daily | 4.4 | true | MSS | 2026-03-15T05:36:00.156906+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_261633 | REC_0012917 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 17.2 | 74 | male | 2 | 16 | 5.5 | 5 | osimertinib 80 mg daily | 8.2 | false | MSS | 2026-03-15T05:36:00.157224+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_370133 | REC_0012918 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 12.2 | 65 | male | 1 | 17 | 7.1 | 2 | osimertinib 80 mg daily | 13.8 | true | MSS | 2026-03-15T05:36:00.157512+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_119925 | REC_0012919 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 8.3 | 67 | female | 1 | 16 | 6.8 | 6 | sotorasib 960 mg daily | 13.5 | false | MSS | 2026-03-15T05:36:00.157791+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_232464 | REC_0012920 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 12 | 3.1 | 73 | female | 1 | 3 | 7.2 | 0 | alectinib 600 mg BID | 11.1 | false | MSS | 2026-03-15T05:36:00.158071+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_734457 | REC_0012921 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 5.3 | 69 | female | 1 | 71 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 27 | false | MSS | 2026-03-15T05:36:00.158369+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_670385 | REC_0012922 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 6.6 | 81 | female | 2 | 20 | 6.5 | 7 | entrectinib 600 mg daily | 13.6 | true | MSS | 2026-03-15T05:36:00.158675+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_430665 | REC_0012923 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 11.5 | 63 | female | 1 | 15 | 6.4 | 5 | alectinib 600 mg BID | 9.4 | false | MSI-H | 2026-03-15T05:36:00.159120+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_282399 | REC_0012924 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 4.8 | 76 | female | 3 | 36 | 6 | 1 | carboplatin + paclitaxel + pembrolizumab | 14.6 | false | MSS | 2026-03-15T05:36:00.159437+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_874332 | REC_0012925 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 9.2 | 70 | female | 2 | 24 | 4.8 | 5 | entrectinib 600 mg daily | 8.4 | true | MSS | 2026-03-15T05:36:00.159730+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_531903 | REC_0012926 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 11.4 | 78 | female | 2 | 16 | 5.1 | 5 | osimertinib 80 mg daily | 11 | false | MSI-H | 2026-03-15T05:36:00.160023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_596882 | REC_0012927 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 6.1 | 69 | male | 1 | 9 | 5.2 | 7 | osimertinib 80 mg daily | 9.3 | false | MSS | 2026-03-15T05:36:00.160376+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_830455 | REC_0012928 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 15.2 | 81 | female | 1 | 22 | 6.8 | 2 | osimertinib 80 mg daily | 18.9 | true | MSS | 2026-03-15T05:36:00.160672+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_478688 | REC_0012929 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 14.6 | 79 | female | 1 | 9 | 6.2 | 4 | alectinib 600 mg BID | 16.4 | true | MSI-H | 2026-03-15T05:36:00.160946+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_431054 | REC_0012930 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 18 | 83 | male | 2 | 11 | 4.6 | 6 | pembrolizumab 200 mg q3w | 14.3 | true | MSS | 2026-03-15T05:36:00.161218+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_684416 | REC_0012931 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 23 | 13.1 | 78 | male | 2 | 16 | 3.8 | 0 | sotorasib 960 mg daily | 37.6 | false | MSS | 2026-03-15T05:36:00.161491+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_329514 | REC_0012932 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 28 | 6.5 | 64 | female | 0 | 10 | 6.4 | 1 | pembrolizumab 200 mg q3w | 13.3 | false | MSS | 2026-03-15T05:36:00.161768+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_154230 | REC_0012933 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 9.7 | 67 | male | 0 | 18 | 6 | 5 | sotorasib 960 mg daily | 24.1 | false | MSS | 2026-03-15T05:36:00.162050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_289783 | REC_0012934 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 20 | 13.2 | 89 | female | 1 | 10 | 4.3 | 0 | sotorasib 960 mg daily | 49 | true | MSI-H | 2026-03-15T05:36:00.162327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_215255 | REC_0012935 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 34 | 10.4 | 57 | male | 1 | 71 | 7.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 16 | true | MSI-H | 2026-03-15T05:36:00.162603+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_236351 | REC_0012936 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 10.2 | 62 | male | 0 | 18 | 7.2 | 6 | sotorasib 960 mg daily | 14.6 | false | MSS | 2026-03-15T05:36:00.163042+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690809 | REC_0012937 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 12.9 | 79 | female | 2 | 18 | 6.1 | 1 | osimertinib 80 mg daily | 20.7 | true | MSI-H | 2026-03-15T05:36:00.163370+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_145280 | REC_0012938 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 12.8 | 70 | male | 0 | 11 | 3.4 | 1 | entrectinib 600 mg daily | 5.5 | true | MSI-H | 2026-03-15T05:36:00.163685+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_596936 | REC_0012939 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 28 | 7.3 | 59 | female | 0 | 7 | 7.2 | 0 | osimertinib 80 mg daily | 17.3 | true | MSS | 2026-03-15T05:36:00.163987+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_743755 | REC_0012940 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 7.1 | 83 | female | 2 | 22 | 5.8 | 4 | pembrolizumab 200 mg q3w | 10.5 | true | MSS | 2026-03-15T05:36:00.164398+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_432231 | REC_0012941 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 9.1 | 68 | female | 0 | 15 | 6.2 | 5 | entrectinib 600 mg daily | 14 | false | MSS | 2026-03-15T05:36:00.164709+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_142568 | REC_0012942 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 15.4 | 70 | female | 1 | 6 | 3.9 | 5 | entrectinib 600 mg daily | 10.5 | true | MSS | 2026-03-15T05:36:00.165041+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_675536 | REC_0012943 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 6.4 | 82 | female | 2 | 35 | 5.3 | 4 | pembrolizumab 200 mg q3w | 18.9 | true | MSS | 2026-03-15T05:36:00.165391+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_853650 | REC_0012944 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 11.1 | 58 | female | 0 | 13 | 4.5 | 2 | entrectinib 600 mg daily | 24.2 | true | MSS | 2026-03-15T05:36:00.165752+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_353352 | REC_0012945 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 28 | 10.2 | 52 | female | 0 | 22 | 5.7 | 0 | entrectinib 600 mg daily | 36.7 | true | MSI-H | 2026-03-15T05:36:00.166106+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_439794 | REC_0012946 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 21 | 5.3 | 64 | male | 1 | 16 | 5.6 | 0 | pembrolizumab 200 mg q3w | 35 | true | MSS | 2026-03-15T05:36:00.166438+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_375521 | REC_0012947 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 9.1 | 63 | female | 0 | 17 | 7 | 6 | osimertinib 80 mg daily | 16.3 | true | MSS | 2026-03-15T05:36:00.166769+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_235475 | REC_0012948 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 15 | 6.7 | 62 | female | 1 | 23 | 5.6 | 4 | entrectinib 600 mg daily | 13.3 | true | MSS | 2026-03-15T05:36:00.167082+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_955004 | REC_0012949 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 22 | 14.5 | 70 | female | 1 | 21 | 7 | 0 | osimertinib 80 mg daily | 33.1 | false | MSS | 2026-03-15T05:36:00.167528+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_212577 | REC_0012950 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 11.7 | 71 | female | 0 | 9 | 4.9 | 6 | pembrolizumab 200 mg q3w | 17.1 | false | MSI-H | 2026-03-15T05:36:00.167853+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546541 | REC_0012951 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 13.6 | 72 | female | 1 | 22 | 6.6 | 1 | osimertinib 80 mg daily | 20.7 | false | MSI-H | 2026-03-15T05:36:00.168269+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_253063 | REC_0012952 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 15 | 5.9 | 57 | male | 0 | 19 | 6.7 | 5 | pembrolizumab 200 mg q3w | 13.3 | true | MSS | 2026-03-15T05:36:00.168627+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_127087 | REC_0012953 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 9.9 | 53 | female | 0 | 18 | 5.8 | 6 | sotorasib 960 mg daily | 12.3 | true | MSS | 2026-03-15T05:36:00.168961+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_805332 | REC_0012954 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 17 | 12.6 | 72 | female | 1 | 16 | 6.3 | 5 | pembrolizumab 200 mg q3w | 15.1 | false | MSI-H | 2026-03-15T05:36:00.169279+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_417731 | REC_0012955 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 4 | 65 | female | 0 | 17 | 6.8 | 5 | sotorasib 960 mg daily | 14.5 | true | MSS | 2026-03-15T05:36:00.169590+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_462232 | REC_0012956 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 10.6 | 69 | female | 1 | 20 | 6.4 | 1 | osimertinib 80 mg daily | 31.3 | false | MSI-H | 2026-03-15T05:36:00.169911+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_632419 | REC_0012957 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 11.7 | 67 | female | 1 | 16 | 5.2 | 5 | alectinib 600 mg BID | 12.8 | false | MSI-H | 2026-03-15T05:36:00.170234+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_880103 | REC_0012958 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 15 | 13.3 | 54 | female | 0 | 16 | 4.2 | 8 | osimertinib 80 mg daily | 9.2 | false | MSS | 2026-03-15T05:36:00.170565+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_837670 | REC_0012959 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 13.3 | 58 | female | 1 | 8 | 4.4 | 2 | osimertinib 80 mg daily | 16.3 | false | MSS | 2026-03-15T05:36:00.170874+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_420935 | REC_0012960 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 22 | 5.9 | 67 | female | 1 | 21 | 6.2 | 0 | osimertinib 80 mg daily | 38.6 | false | MSS | 2026-03-15T05:36:00.171184+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_717573 | REC_0012961 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 12.9 | 63 | male | 1 | 7 | 5.3 | 2 | sotorasib 960 mg daily | 23.5 | false | MSS | 2026-03-15T05:36:00.171512+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593024 | REC_0012962 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 34 | 13.7 | 55 | male | 0 | 20 | 4.2 | 7 | alectinib 600 mg BID | 5.1 | false | MSS | 2026-03-15T05:36:00.172022+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_510507 | REC_0012963 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 15.7 | 55 | female | 1 | 17 | 4.9 | 2 | osimertinib 80 mg daily | 21.6 | false | MSI-H | 2026-03-15T05:36:00.172552+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_393840 | REC_0012964 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 7.9 | 71 | female | 2 | 21 | 5.8 | 6 | osimertinib 80 mg daily | 14.3 | true | MSS | 2026-03-15T05:36:00.172882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_805910 | REC_0012965 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 7.9 | 58 | male | 0 | 17 | 3.6 | 6 | alectinib 600 mg BID | 9.4 | true | MSS | 2026-03-15T05:36:00.173386+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_760362 | REC_0012966 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 16.1 | 90 | male | 2 | 18 | 7.2 | 2 | osimertinib 80 mg daily | 15.1 | true | MSI-H | 2026-03-15T05:36:00.173722+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_839983 | REC_0012967 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 9.3 | 65 | female | 1 | 17 | 2.6 | 6 | entrectinib 600 mg daily | 9.2 | true | MSS | 2026-03-15T05:36:00.174020+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_987497 | REC_0012968 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 19 | 5.1 | 63 | male | 1 | 25 | 6 | 6 | pembrolizumab 200 mg q3w | 12.5 | false | MSS | 2026-03-15T05:36:00.174290+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_100121 | REC_0012969 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 19.8 | 67 | female | 1 | 10 | 7.5 | 2 | alectinib 600 mg BID | 24.8 | false | MSI-H | 2026-03-15T05:36:00.174568+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_119655 | REC_0012970 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 10.5 | 64 | female | 0 | 22 | 6.7 | 2 | osimertinib 80 mg daily | 17.7 | false | MSI-H | 2026-03-15T05:36:00.174863+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450397 | REC_0012971 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 6.7 | 83 | female | 2 | 16 | 3.6 | 1 | osimertinib 80 mg daily | 23.6 | true | MSS | 2026-03-15T05:36:00.175167+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_650806 | REC_0012972 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 16 | 12 | 63 | male | 1 | 0 | 4 | 1 | alectinib 600 mg BID | 23 | true | MSS | 2026-03-15T05:36:00.175477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_724786 | REC_0012973 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 15 | 6.1 | 53 | male | 0 | 55 | 5.1 | 7 | pembrolizumab 200 mg q3w | 8.9 | true | MSS | 2026-03-15T05:36:00.175776+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_270321 | REC_0012974 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 13.3 | 82 | female | 1 | 5 | 6.3 | 6 | osimertinib 80 mg daily | 6 | false | MSS | 2026-03-15T05:36:00.176069+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_136305 | REC_0012975 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 17.1 | 68 | female | 1 | 15 | 6.9 | 5 | entrectinib 600 mg daily | 12.4 | true | MSI-H | 2026-03-15T05:36:00.185184+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_333253 | REC_0012976 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 10.2 | 54 | female | 0 | 17 | 7.1 | 4 | alectinib 600 mg BID | 12.7 | false | MSI-H | 2026-03-15T05:36:00.186590+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_671371 | REC_0012977 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 6 | 59 | male | 1 | 14 | 4.5 | 4 | alectinib 600 mg BID | 4.8 | true | MSS | 2026-03-15T05:36:00.186971+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_237370 | REC_0012978 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 17 | 9.6 | 68 | male | 0 | 11 | 5.9 | 1 | osimertinib 80 mg daily | 21.7 | false | MSS | 2026-03-15T05:36:00.187265+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459162 | REC_0012979 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 15.5 | 66 | female | 1 | 15 | 4.9 | 2 | alectinib 600 mg BID | 15.8 | true | MSS | 2026-03-15T05:36:00.187668+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_744415 | REC_0012980 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 13.7 | 78 | female | 1 | 10 | 6 | 7 | alectinib 600 mg BID | 12 | true | MSS | 2026-03-15T05:36:00.187994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_750845 | REC_0012981 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 6.5 | 63 | female | 1 | 17 | 6.4 | 4 | sotorasib 960 mg daily | 4 | false | MSS | 2026-03-15T05:36:00.188401+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_622078 | REC_0012982 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 13.5 | 71 | female | 1 | 7 | 5.6 | 1 | sotorasib 960 mg daily | 25.6 | false | MSI-H | 2026-03-15T05:36:00.188705+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849887 | REC_0012983 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 12 | 53 | female | 0 | 4 | 5.7 | 5 | osimertinib 80 mg daily | 9.3 | true | MSI-H | 2026-03-15T05:36:00.189008+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_311954 | REC_0012984 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 5.9 | 76 | female | 1 | 44 | 7.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 17.6 | true | MSS | 2026-03-15T05:36:00.189288+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_307674 | REC_0012985 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 23 | 4.1 | 52 | male | 0 | 67 | 5.6 | 0 | carboplatin + paclitaxel + pembrolizumab | 43.3 | true | MSS | 2026-03-15T05:36:00.189583+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_181807 | REC_0012986 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 10.9 | 76 | female | 1 | 10 | 3.9 | 8 | osimertinib 80 mg daily | 13.7 | true | MSI-H | 2026-03-15T05:36:00.189864+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_386083 | REC_0012987 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 9.3 | 67 | male | 0 | 15 | 5.8 | 4 | entrectinib 600 mg daily | 14.8 | true | MSS | 2026-03-15T05:36:00.190130+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_631911 | REC_0012988 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 9.1 | 52 | male | 0 | 14 | 4 | 2 | osimertinib 80 mg daily | 18.5 | true | MSS | 2026-03-15T05:36:00.190530+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_437032 | REC_0012989 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 7.5 | 73 | female | 1 | 10 | 4.6 | 1 | sotorasib 960 mg daily | 17.6 | true | MSS | 2026-03-15T05:36:00.199769+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_560920 | REC_0012990 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 8.8 | 63 | male | 0 | 17 | 6.3 | 5 | osimertinib 80 mg daily | 8.4 | false | MSS | 2026-03-15T05:36:00.201729+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_279691 | REC_0012991 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 13.3 | 64 | female | 1 | 16 | 4 | 6 | osimertinib 80 mg daily | 14.5 | false | MSS | 2026-03-15T05:36:00.206809+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450111 | REC_0012992 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 9.8 | 62 | male | 1 | 20 | 5 | 3 | osimertinib 80 mg daily | 8.9 | true | MSS | 2026-03-15T05:36:00.207218+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_148185 | REC_0012993 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 19 | 12.4 | 68 | female | 0 | 4 | 6 | 2 | pembrolizumab 200 mg q3w | 22.3 | false | MSI-H | 2026-03-15T05:36:00.207554+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648686 | REC_0012994 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 2.4 | 65 | male | 0 | 36 | 5.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 7.3 | true | MSS | 2026-03-15T05:36:00.207885+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_749327 | REC_0012995 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 12.7 | 62 | female | 1 | 12 | 4.5 | 2 | osimertinib 80 mg daily | 9.5 | false | MSI-H | 2026-03-15T05:36:00.208315+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_286830 | REC_0012996 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 16.7 | 68 | female | 0 | 24 | 5.8 | 6 | alectinib 600 mg BID | 8.8 | true | MSS | 2026-03-15T05:36:00.208692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_947913 | REC_0012997 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 15.5 | 52 | male | 0 | 14 | 5 | 5 | entrectinib 600 mg daily | 16.2 | false | MSI-H | 2026-03-15T05:36:00.209021+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_339650 | REC_0012998 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 14.1 | 57 | female | 1 | 28 | 5.3 | 5 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:36:00.209350+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_485968 | REC_0012999 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 17.8 | 55 | male | 0 | 18 | 5.4 | 5 | alectinib 600 mg BID | 15.2 | false | MSS | 2026-03-15T05:36:00.209659+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855142 | REC_0013000 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 16 | 9.3 | 51 | male | 0 | 17 | 5.5 | 8 | sotorasib 960 mg daily | 9.6 | true | MSS | 2026-03-15T05:36:00.209966+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.